The joint effort builds on ContextVision’s clinical partnership with the University of Washington (USA), where a clinical evaluation is underway to acquire imaging data for the development of a multiparameter biomarker for MASLD, states the company. 

AMRA Medical now joins this effort by adding their MRI-based analysis for measuring liver fat (PDFF), abdominal fat volumes, and detailed muscle assessment. AMRAs contribution will further enrich the multimodal dataset by enabling correlations between MRI and ultrasound imaging biomarkers thereby strengthening ContextVision’s development of disease staging solutions, states ContextVision.

Advance liver diagnosis

“As we build out our Data Quality business, partnerships like this are essential,” says Gerald Pötzsch, CEO of ContextVision. “AMRA’s highly detailed MRI measurements, add critical value to our clinical data pipeline. Together, we are moving closer to a new standard in liver disease diagnostics – non-invasive, accurate, and scalable.”

MASLD affects approximately one in four people globally and is rapidly becoming one of the leading causes of chronic liver disease. The need for non-invasive, cost-effective diagnostic solutions is urgent – particularly as current methods often miss early stages of disease. By integrating MRI and ultrasound technologies through this partnership, ContextVision and AMRA Medical aim to deliver actionable, multimodal biomarkers to improve early detection and treatment planning for millions of patients.